The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
Abstract
Fecal microbiota transplantation (FMT) represents a potential strategy to overcome resistance to immune checkpoint inhibitors in patients with refractory melanoma; however, the role of FMT in first-line treatment settings has not been evaluated. We conducted a multicenter phase I trial combining healthy donor FMT with the PD-1 inhibitors nivolumab or pembrolizumab in 20 previously untreated patients with advanced melanoma. The primary end point was safety. No grade 3 adverse events were reported from FMT alone. Five patients (25%) experienced grade 3 immune-related adverse events from combination therapy. Key secondary end points were objective response rate, changes in gut microbiome composition and systemic immune and metabolomics analyses. The objective response rate was 65% (13 of 20), including four (20%) complete responses. Longitudinal microbiome profiling revealed that all patients engrafted strains from their respective donors; however, the acquired similarity between donor and patient microbiomes only increased over time in responders. Responders experienced an enrichment of immunogenic and a loss of deleterious bacteria following FMT. Avatar mouse models confirmed the role of healthy donor feces in increasing anti-PD-1 efficacy. Our results show that FMT from healthy donors is safe in the first-line setting and warrants further investigation in combination with immune checkpoint inhibitors. ClinicalTrials.gov identifier NCT03772899 .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Stable taxa and functions are enriched in therapy responders across multiple cohorts, further supporting the idea that a resilient microbiome underpins effective ICI therapies.190,229”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [229]
In the citing paper
“These studies demonstrated that recipients’ gut microbiota diverged from baseline after FMT and matched those of their respective donors.229,231,232”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [229]
In the citing paper
“Stable taxa and functions are enriched in therapy responders across multiple cohorts, further supporting the idea that a resilient microbiome underpins effective ICI therapies.190,229”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [229]
In the citing paper
“The longest follow-up among FMT trials for cancer patients has been 3 months.229,231,232,234”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [229]
In the citing paper
“Pioneering studies in mice and melanoma patients have already demonstrated its safety and efficacy in improving anti-PD1 therapy,13,229,231,232,235 and additional studies and meta-analyses are investigating its mechanism of action.230,234”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [229]
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
DADA2: High–resolution sample inference from Illumina amplicon data
Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016) · Nature Methods · doi:10.1038/nmeth.3869 · Cited by 35,698
The SILVA ribosomal RNA gene database project: improved data processing and web-based tools
Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., & Glöckner, F. O. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1219 · Cited by 33,055
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data
McMurdie, P. J., & Holmes, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061217 · Cited by 21,322
Random effects structure for confirmatory hypothesis testing: Keep it maximal
Barr, D. J., Levy, R., Scheepers, C., & Tily, H. J. (2013) · Journal of Memory and Language · doi:10.1016/j.jml.2012.11.001 · Cited by 10,328
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Smith, C. A., Want, E. J., O'Maille, G., Abagyan, R., & Siuzdak, G. (2006) · Analytical Chemistry · doi:10.1021/ac051437y · Cited by 5,262
Cited by
Fecal microbiota transplantation: current challenges and future landscapes
Yadegar, A., Bar-Yoseph, H., Monaghan, T. M., Pakpour, S., Severino, A., Kuijper, E. J., Smits, W. K., Terveer, E. M., Neupane, S., Nabavi-Rad, A., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00060-22 · Cited by 351
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
Holder, A. M., Dedeilia, A., Sierra-Davidson, K., Cohen, S., Liu, D., Parikh, A., & Boland, G. M. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00705-7 · Cited by 298
Human trials exploring anti-aging medicines
Guarente, L., Sinclair, D. A., & Kroemer, G. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.007 · Cited by 244
Current and future immunotherapeutic approaches in pancreatic cancer treatment
Farhangnia, P., Khorramdelazad, H., Nickho, H., & Delbandi, A.-A. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01561-6 · Cited by 229
Exploiting bacteria for cancer immunotherapy
Kwon, S.-Y., Thi-Thu Ngo, H., Son, J., Hong, Y., & Min, J.-J. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00908-9 · Cited by 201
“Consequently, FMT is currently being explored in multiple clinical trials as a supplementary therapy to improve the clinical efficacy of ICIs.”
Influential
Metadata
- Authors
- Routy, B., Lenehan, J. G., Miller, W. H., Jamal, R., Messaoudene, M., Daisley, B. A., Hes, C., Al, K. F., Martinez-Gili, L., Punčochář, M., Ernst, S., Logan, D., Belanger, K., Esfahani, K., Richard, C., Ninkov, M., Piccinno, G., Armanini, F., Pinto, F., Krishnamoorthy, M., Figueredo, R., Thebault, P., Takis, P., Magrill, J., Ramsay, L., Derosa, L., Marchesi, J. R., Parvathy, S. N., Elkrief, A., Watson, I. R., Lapointe, R., Segata, N., Haeryfar, S. M. M., Mullish, B. H., Silverman, M. S., Burton, J. P., & Maleki Vareki, S.
- Affiliations
- Centre Hospitalier de l’Université de Montréal (CA)
- Western University (CA)
- Jewish General Hospital (CA)
- University of Trento (IT)
- Imperial College London (GB)
- Institut du cancer Rosalind & Morris Goodman (CA)
- Inserm (FR)
- St Mary's Hospital (GB)
- Imperial College Healthcare NHS Trust (GB)
- ORCID
- Routy, Bertrand
- Lenehan, John G.
- Miller, Wilson H.
- Messaoudene, Meriem
- Daisley, Brendan A.
- Hes, Cecilia
- Al, Kait F.
- Martinez-Gili, Laura
- Punčochář, Michal
- Ernst, Scott
- Esfahani, Khashayar
- Richard, Corentin
- Ninkov, Marina
- Piccinno, Gianmarco
- Armanini, Federica
- Pinto, Federica
- Krishnamoorthy, Mithunah
- Takis, Panteleimon
- Magrill, Jamie
- Derosa, Lisa
- Marchesi, Julian R.
- Parvathy, Seema Nair
- Elkrief, Arielle
- Watson, Ian R.
- Segata, Nicola
- Haeryfar, S.M. Mansour
- Mullish, Benjamin H.
- Silverman, Michael S.
- Burton, Jeremy P.
- Maleki Vareki, Saman
- Venue
- Nature Medicine
- Published
- 2023-07-06
- Volume
- 29
- Issue
- 8
- Pages
- 2121-2132
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4383341159
- Cited by
- 526
- References
- 76
- Citations by year
- 2026: 174 · 2025: 197 · 2024: 132 · 2023: 22
- FWCI
- 64.04
- Type
- journal article
- Language
- en
- Update notices
- correction (2023-11-03)
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System (Università degli Studi di Trento) (submittedVersion)
- Funders
- Lotte and John Hecht Memorial Foundation
- Canadian Institute of Health Research
- Canadian Cancer Society Impact Grant
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- fecal microbiota transplantation, anti-PD-1 therapy, advanced melanoma, nivolumab, pembrolizumab, immune checkpoint inhibitors, first-line therapy, gut microbiota, immune-related adverse events, donor engraftment
- MeSH terms
- Fecal Microbiota Transplantation, Immune Checkpoint Inhibitors, Animals, Feces, Humans, Immunotherapy, Melanoma, Treatment Outcome, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. https://app.cochat.ai/papers/10.1038/s41591-023-02453-x
- The paper
- Routy, B., Lenehan, J. G., Miller, W. H., Jamal, R., Messaoudene, M., Daisley, B. A., Hes, C., Al, K. F., Martinez-Gili, L., Punčochář, M., Ernst, S., Logan, D., Belanger, K., Esfahani, K., Richard, C., Ninkov, M., Piccinno, G., Armanini, F., Pinto, F., . . . Maleki Vareki, S. (2023). Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nature Medicine. https://doi.org/10.1038/s41591-023-02453-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.